{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:37:20Z","timestamp":1782283040848,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["americanjournalofsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Surgery"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.amjsurg.2013.08.002","type":"journal-article","created":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T07:30:15Z","timestamp":1378452615000},"page":"704-708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Review of risk factors for the development of contralateral breast cancer"],"prefix":"10.1016","volume":"206","author":[{"given":"Ingrid M.","family":"Lizarraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia L.","family":"Sugg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol E.H.","family":"Scott-Conner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjsurg.2013.08.002_bib1","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1245\/s10434-012-2525-x","article-title":"Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age","volume":"19","author":"Fisher","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib2","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1200\/JCO.2010.33.4482","article-title":"Contralateral prophylactic mastectomy: what do we know and what do our patients know?","volume":"29","author":"Khan","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib3","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1200\/JCO.2010.29.4041","article-title":"Clinical management factors contribute to the decision for contralateral prophylactic mastectomy","volume":"29","author":"King","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib4","article-title":"Prophylactic mastectomy for the prevention of breast cancer","volume":"11","author":"Lostumbo","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib5","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S0360-3016(03)00203-7","article-title":"Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study","volume":"56","author":"Gao","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib6","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/jnci\/djp181","article-title":"Second primary breast cancer occurrence according to hormone receptor status","volume":"101","author":"Kurian","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10549-012-2183-5","article-title":"Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer","volume":"135","author":"Saltzman","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib8","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2010.32.7395","article-title":"Declining incidence of contralateral breast cancer in the United States from 1975 to 2006","volume":"20","author":"Nichols","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib9","series-title":"New Malignancies Among Cancer Survivors: SEER Cancer Registries 1973-2000","author":"Curtis","year":"2006"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib10","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/1097-0215(20001215)88:6<998::AID-IJC25>3.0.CO;2-0","article-title":"Risk factors and age-incidence relationships for contralateral breast cancer","volume":"88","author":"Vaittinen","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib11","doi-asserted-by":"crossref","first-page":"e46535","DOI":"10.1371\/journal.pone.0046535","article-title":"Estrogen receptor status in relation to risk of contralateral breast cancer-a population-based cohort study","volume":"7","author":"Sandberg","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib12","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2006.10.5056","article-title":"Incidence and prognosis of synchronous and metachronous bilateral breast cancer","volume":"25","author":"Hartman","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10549-010-1137-z","article-title":"Risk of second breast cancer according to estrogen receptor status and family history","volume":"127","author":"Bouchardy","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib14","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ejca.2011.05.004","article-title":"Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways","volume":"47","author":"Vichapat","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1053\/ejso.1999.0711","article-title":"Clinical and histological predictors of contralateral breast cancer","volume":"25","author":"Kollias","year":"1999","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib16","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib17","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.2010.34.0141","article-title":"Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24","volume":"30","author":"Allred","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib18","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/1055-9965.EPI-10-1016","article-title":"Risk of a second breast cancer associated with hormone-receptor and HER2\/neu status of the first breast cancer","volume":"20","author":"Bessonova","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib20","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(11)70033-X","article-title":"Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial","volume":"12","author":"Gianni","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/01.ede.0000072105.39021.6d","article-title":"The descriptive epidemiology of second primary breast cancer","volume":"14","author":"Bernstein","year":"2003","journal-title":"Epidemiology"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-010-1324-y","article-title":"Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer","volume":"129","author":"Schairer","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2012.43.2013","article-title":"Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study","volume":"31","author":"Reiner","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib25","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1186\/bcr3369","article-title":"The risk of contralateral breast cancer in patients from BRCA1\/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study","volume":"14","author":"Rhiem","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib26","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/0008-5472.CAN-06-3854","article-title":"Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk","volume":"6","author":"Hemminki","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib27","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib28","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib29","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","article-title":"Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"22","author":"Metcalfe","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib30","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","article-title":"Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"27","author":"Graeser","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib31","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1200\/JCO.2009.24.2495","article-title":"Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2","volume":"28","author":"Malone","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib32","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/bjc.2011.120","article-title":"Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"104","author":"Metcalfe","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/jnci\/djq018","article-title":"Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients","volume":"102","author":"Bedrosian","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.amjsurg.2013.08.002_bib34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/EDE.0b013e318190eee6","article-title":"Age-specific incidence of breast cancer in breast cancer survivors and their first-degree relatives","volume":"20","author":"Bertelsen","year":"2009","journal-title":"Epidemiology"}],"container-title":["The American Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961013004157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961013004157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:02:59Z","timestamp":1757700179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002961013004157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0002961013004157"],"URL":"https:\/\/doi.org\/10.1016\/j.amjsurg.2013.08.002","relation":{},"ISSN":["0002-9610"],"issn-type":[{"value":"0002-9610","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of risk factors for the development of contralateral breast cancer","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjsurg.2013.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}